These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 23612993)
41. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410 [TBL] [Abstract][Full Text] [Related]
42. [As simple and as compatible as possible. HIV patients profit from single tablet regimen]. MMW Fortschr Med; 2014 Jun; 156 Suppl 1():46-7. PubMed ID: 25026857 [No Abstract] [Full Text] [Related]
43. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond. Murphy RL AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882 [TBL] [Abstract][Full Text] [Related]
44. "Solving the puzzle" of current HAART: what key strategic trials are needed? Carosi G; Torti C New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075 [TBL] [Abstract][Full Text] [Related]
45. Is Hydroxyurea for real? Mascolini M J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731 [TBL] [Abstract][Full Text] [Related]
46. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. Klibanov OM; Kaczor RL Curr Opin Investig Drugs; 2010 Feb; 11(2):237-45. PubMed ID: 20112173 [TBL] [Abstract][Full Text] [Related]
47. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Uckun FM Arzneimittelforschung; 2006 Feb; 56(2A):121-35. PubMed ID: 16570821 [TBL] [Abstract][Full Text] [Related]
48. Nucleoside analogues in 2008. Warwick Z; Churchill D J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267 [No Abstract] [Full Text] [Related]
49. Vaginal microbicides: moving ahead after an unexpected setback. van de Wijgert JH; Shattock RJ AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873 [No Abstract] [Full Text] [Related]
50. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Miller V; Grant RM Clin Pharmacol Ther; 2014 Aug; 96(2):153-5. PubMed ID: 25056397 [TBL] [Abstract][Full Text] [Related]
51. Preclinical discovery and development of maraviroc for the treatment of HIV. Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601 [TBL] [Abstract][Full Text] [Related]
52. The NCI's AIDS antiviral drug screening program. Yang SS Leukemia; 1995 Oct; 9 Suppl 1():S9-11. PubMed ID: 7475324 [TBL] [Abstract][Full Text] [Related]
53. Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. Hadas E; Borjabad A; Chao W; Saini M; Ichiyama K; Potash MJ; Volsky DJ AIDS; 2007 May; 21(8):905-9. PubMed ID: 17457083 [TBL] [Abstract][Full Text] [Related]
54. Microbicides for multidrug-resistant and multitropic HIV-1. D'Cruz OJ; Uckun FM Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518 [TBL] [Abstract][Full Text] [Related]
55. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication? Lavigne C; Yelle J; Sauve G; Thierry AR AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618 [TBL] [Abstract][Full Text] [Related]
56. The role of resistance testing in clinical trial design and product labelling: a regulatory perspective. Laessig KA; Murray JS; Chikami G Antivir Ther; 2000 Mar; 5(1):77-83. PubMed ID: 10846597 [TBL] [Abstract][Full Text] [Related]
57. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. du Toit LC; Pillay V; Choonara YE Adv Drug Deliv Rev; 2010 Mar; 62(4-5):532-46. PubMed ID: 19922751 [TBL] [Abstract][Full Text] [Related]
58. Targeted therapeutics--from chemical structures to diagnostic and therapeutic agents. Armbruster C Curr Pharm Des; 2009; 15(2):118-9. PubMed ID: 19149607 [No Abstract] [Full Text] [Related]
59. Ex Vivo Metrics, a preclinical tool in new drug development. Curtis CG; Bilyard K; Stephenson H J Transl Med; 2008 Jan; 6():5. PubMed ID: 18215298 [TBL] [Abstract][Full Text] [Related]
60. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Green JD; Black LE Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]